Tags: Drug.

Farglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by GlaxoSmithKline for the treatment of hepatic fibrosis. It is currently in phase II clinical trials.

Farglitazar.svg
ATC prefix
none
CAS number
196808-45-4
FDA UNII code
3433GY7132
IUPAC name
N-(o-benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-(L)-tyrosine
PubChem
170364

Loading...

This page contains content from the copyrighted Wikipedia article "Farglitazar"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.